Tyrosine Protein Kinase Mer - Pipeline Review, H2 2020
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 18.104.22.168) pipeline Target constitutes close to 19 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase Mer - Pipeline Review, H2 2020, outlays comprehensive information on the Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 22.214.171.124) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 126.96.36.199) - Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells. It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.
The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 9 and 3 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Oncology and Ophthalmology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Melanoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Gastric Cancer, Glioblastoma Multiforme (GBM), Metastatic Colorectal Cancer, Ovarian Cancer, Triple-Negative Breast Cancer (TNBC), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Esophageal Cancer, Gallbladder Cancer, Hematological Tumor, Hepatocellular Carcinoma, Lung Cancer, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Melanoma, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Pancreatic Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Renal Cell Carcinoma, Retinitis Pigmentosa (Retinitis), Soft Tissue Sarcoma and Transitional Cell Cancer (Urothelial Cell Cancer).
Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 188.8.131.52) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook